Viking Therapeutics, Inc. (VKTX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Diego, CA, United States. El CEO actual es Brian Lian.
VKTX tiene fecha de IPO 2015-04-28, 45 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $4.1B.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for metabolic and endocrine disorders. The company's lead candidate, VK2809, is an orally available thyroid hormone receptor beta agonist currently in Phase IIb trials for non-alcoholic steatohepatitis and fatty liver disease. Viking's pipeline also includes VK5211, a selective androgen receptor modulator in Phase II development for hip fracture recovery; VK0612, a Phase IIb-ready candidate for type 2 diabetes; and VK0214, another thyroid hormone receptor beta agonist for X-linked adrenoleukodystrophy. Founded in 2012, the company focuses on addressing significant unmet medical needs in metabolic and endocrine disease treatment.
